FDA clears GE Healthcare's vascular vision software

GE Healthcare has received FDA clearance of AngioViz, an application that provides visualization of vascular flow on a single image.

AngioViz provides visualization of the vascular flow seen in Digital Subtraction Angiography (DSA) imaging utilizing a technique called parametric imaging.

AngioViz looks at each pixel in the image series and determines the peak value of opacification caused by the contrast and the time it takes for that pixel to reach peak opacification. These two parameters can be displayed as separate images or combined into a single color-coded image that represents parameters of vascular flow to enable physicians to perceive parameters of flow to support decisionmaking.

In addition, AngioViz allows comparison of parametric images from different DSA acquisitions, such as pre- and post-treatment images, according to Waukesha, Wis.-based GE Healthcare.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.